Dogwood Therapeutics, Inc. (DWTX) News
Follow Dogwood Therapeutics, Inc. (DWTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
DWTX Halneuron reports significant, durable pain relief in CINP Phase 2
Halneuron, a synthetic NaV1.7 inhibitor, showed significant and durable pain relief in CINP patients in Phase 2. Company says manufacturing is scalable and a Phase 2b data readout is expected in Fall 2026.
REGULATION | Sep 01, 2026, 06:23 PM UTC
L
DWTX says Halneuron shows durable efficacy in chemotherapy neuropathic pain
DWTX’s Halneuron, a selective NaV1.7 inhibitor, is described as targeting chemotherapy-induced neuropathic pain with durable efficacy and strong tolerability in clinical trials. Company says synthetic TTX manufacturing s
EQUITY | Sep 01, 2026, 05:28 PM UTC
L
DWTX highlights Halneuron potential for chemotherapy-induced neuropathic pain
Halneuron, a selective NaV1.7 inhibitor, is positioned as a first-in-class, durable therapy for chemotherapy-induced neuropathic pain, citing durable efficacy and a strong safety profile in clinical trials.
EQUITY | Sep 01, 2026, 04:08 PM UTC
L
DWTX - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 20
DWTX - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
EQUITY | Aug 17, 2026, 12:30 PM UTC
L
Dogwood Therapeutics reports Second Quarter 2026 financial results
Dogwood Therapeutics (DWTX) announces its Second Quarter 2026 financial results, with no additional figures or guidance included in the provided feed.
EARNINGS | Aug 13, 2026, 12:30 PM UTC